Phase II PCYC-1111 Trial of Ibrutinib with or without Dexamethasone in Relapsed/Refractory MM


Phase II PCYC-1111 Trial of Ibrutinib with or without Dexamethasone in Relapsed/Refractory MM
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Ola Landgren, MD, PhD (2/9/15)
Vij R et al. Ibrutinib, single agent or in combination with dexamethasone, in patients with relapsed or relapsed/refractory multiple myeloma (MM): Preliminary phase 2 results. Proc ASH 2014;Abstract 31.

Dr Landgren is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center in New York, New York.